Roche’s Tecentriq becomes the first ever subcutaneous injectable PD-L1 inhibitor for a range of cancers in Europe – a real game changer.
Roche and its co-developer Halozyme reported that the European Commission has approved its marketing approval for the subcutaneous injectable form of its PD-L1 inhibitor Tecentriq (atezolizumab) for multiple cancer types – the first ever SC injectable PD-L1 cancer immunotherapy in the EU . This approval is NOT about how clinically efficacious Tecentriq is; we know it is. This approval is about making Tecentriq more accessible and easier for the patient, easier for the doctors and easier for the healthcare system – a genuine game changer. Read-out of data from the pivotal phase 1b/3 IMscin001 trial demonstrated comparable levels of subcutaneous atezolizumab in the blood and a similar safety and efficacy profile to that of the IV formulation. Treatment time will reduce by approximately 80%, with most injections taking between 4 to 8 minutes compared with 30 to 60 minutes for an intravenous (IV) infusion. Potentially outpatient and home SC shots are now realistic compared to booking hospital beds for an hour-long IV drip. A definite bonus for the patient, doctor and healthcare system.
READ THE ARTICLE – https://www.pmlive.com/pharma_news/roches_subcutaneous_tecentriq_granted_ec_approval_for_multiple_cancer_types_1506729